| CAS ID: | 3424-98-4 |
| Molecular Formula: | C10H14N2O5 |
| Molecular Weight: | 242.2 g/mol |
| Monoisotopic Mass: | 242.0903 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | NV-02B | SEBIVO | TYZEKA | TELBIVUDINE |
| Analysis: | Drug repositioning mechanism analysis |
Reference Record 1
| PubMed ID | 24067902 | Target ID | |
| Uniprot ID | Name | ||
| Model | vitro,human | Fibrosis Disease | Liver fibrosis |
| Process I | attenue inflammation | ||
| Process II | |||
| Process III | prevenet collagen deposition | ||
| Mechanism | |||
Trial Record 1
| ClinicalTrial ID | NCT01799486 | Disease | Liver fibrosis |
| Phase | Phase 4 | Status | Unknown |
| First Received | February 26, 2013 | Last Verified | February 26, 2013 |
| Sponsor | Lin Bingliang | ||
Trial Record 2
| ClinicalTrial ID | NCT01718587 | Disease | Liver fibrosis |
| Phase | Phase 1,Phase 2 | Status | Unknown |
| First Received | October 31, 2012 | Last Verified | October 31, 2012 |
| Sponsor | General Hospital of Chinese Armed Police Forces | ||
Trial Record 3
| ClinicalTrial ID | NCT01693679 | Disease | Liver fibrosis |
| Phase | Phase 4 | Status | Unknown |
| First Received | September 26, 2012 | Last Verified | September 26, 2012 |
| Sponsor | Shao-quan Zhang | ||
Trial Record 4
| ClinicalTrial ID | NCT01380951 | Disease | Liver fibrosis |
| Phase | Phase 4 | Status | Unknown |
| First Received | June 27, 2011 | Last Verified | June 27, 2011 |
| Sponsor | The Fifth People's Hospital of Suzhou | ||
Trial Record 5
| ClinicalTrial ID | NCT00275652 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | January 12, 2006 | Last Verified | March 23, 2011 |
| Sponsor | Mayo Clinic | ||
Trial Record 6
| ClinicalTrial ID | NCT00076336 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | January 22, 2004 | Last Verified | September 5, 2011 |
| Sponsor | Novartis Pharmaceuticals | ||
| PubChem: | 159269 |
| ChEMBL: | CHEMBL374731 |